GSK discloses shareholder reaching 5.01% voting stake

GSK plc reports a change in a major shareholding, as a notification under the TR-1 regime shows the holder’s total voting interest reaching 5.010000% of voting rights in the company.

Rhea-AI Filing Summary

GSK plc reports a change in a major shareholding, as a notification under the TR-1 regime shows the holder’s total voting interest reaching 5.010000% of voting rights in the company. This corresponds to 203,320,168 voting rights in total, up from a previously reported position of 4.930000%.

The interest is held entirely through shares rather than derivative or other financial instruments. It includes voting rights linked to ordinary shares with ISIN GB00BN7SWP63 and to ADRs with ISIN US37733W2044. No additional voting rights are reported through financial instruments in this notification.

Insights

Equity Ownership Analyst

GSK discloses a shareholder crossing the 5% voting rights threshold.

The notification shows a holder increasing their total voting rights from 4.930000% to 5.010000%, or 203,320,168 voting rights. This crosses the UK disclosure threshold that triggers a TR-1 major holdings filing.

The position is held entirely via ordinary shares and ADRs, with no additional exposure through financial instruments, which simplifies the ownership structure. Future TR-1 updates in company disclosures may show whether this stake continues to grow or stabilises around the current level.

Key Figures

Current voting rights percentage: 5.010000% Total voting rights held: 203,320,168 voting rights Previous voting rights percentage: 4.930000% +3 more

6 metrics

Current voting rights percentage 5.010000% Resulting situation after threshold crossed

Total voting rights held 203,320,168 voting rights Resulting situation after threshold crossed

Previous voting rights percentage 4.930000% Position of previous notification

Ordinary share voting rights 88,958,040 voting rights Ordinary shares ISIN GB00BN7SWP63, indirect voting rights

ADR voting rights 114,362,128 voting rights ADRs ISIN US37733W2044, indirect voting rights

Voting rights via financial instruments 0.000000% Financial instruments 8.B1 and 8.B2

Key Terms

TR-1, voting rights attached to shares, financial instruments, ADRs, +1 more

5 terms

TR-1 regulatory

"TR-1: Standard form for notification of major holdings"

A TR-1 is a financial form used by investors to report significant ownership stakes in a company, typically when they acquire or dispose of a large number of shares. It helps keep the market informed about major shareholders and potential changes in control, allowing other investors to make better-informed decisions. This transparency encourages fair trading and reduces surprises related to ownership shifts.

voting rights attached to shares financial

"% of voting rights attached to shares (total of 8.A)"

financial instruments financial

"% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)"

Financial instruments are assets or contracts that hold monetary value and can be bought, sold, or traded. They serve as tools for investors to grow, protect, or transfer money, much like how a ticket or voucher can be used to access goods or services. These instruments help individuals and organizations manage financial goals and risks across different markets and economic conditions.

ADRs financial

"ADRs US37733W2044 | | 114362128 | | 20"

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

proxy voting regulatory

"10. In case of proxy voting Name of the proxy holder"

Proxy voting is a process that allows investors to have their voting power on company decisions exercised by someone else if they cannot attend meetings in person. It ensures that their opinions are still represented, similar to authorizing someone else to vote on their behalf at an election. This helps investors influence company actions even when they cannot be physically present.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What major shareholding change did GSK (GSK) report in this filing?

GSK reported a TR-1 notification showing a shareholder’s total voting interest at 5.010000%, representing 203,320,168 voting rights. This reflects an increase from a previously disclosed level of 4.930000%, indicating the holder crossed the 5% major shareholding threshold.

How many GSK voting rights are now held by the notified shareholder?

The notified shareholder now holds 203,320,168 voting rights in GSK. This total corresponds to a 5.010000% voting interest, as disclosed in the TR-1 notification, and is higher than the previously reported level of 4.930000% voting rights.

Does the GSK (GSK) TR-1 notification include financial instruments?

No, the TR-1 notification shows the stake is held entirely through shares. The filing reports 5.010000% voting rights attached to shares and 0.000000% through financial instruments, with no additional voting rights arising from derivatives or similar instruments.

What types of securities comprise the reported GSK voting rights?

The reported voting rights are linked to GSK ordinary shares and ADRs. Ordinary shares carry voting rights under ISIN GB00BN7SWP63, while ADRs carry voting rights under ISIN US37733W2044, combining to reach the disclosed 203,320,168 voting rights in total.

Why is the 5% threshold important for GSK (GSK) shareholders?

Crossing the 5% threshold triggers a mandatory TR-1 disclosure of major holdings under UK rules. It signals that an investor has accumulated a sizeable voting position, providing transparency about significant ownership interests in GSK’s share capital for the broader market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 10:02 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN7SWP63

Issuer Name

GSK PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Dodge & Cox

City of registered office (if applicable)

San Francisco

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

23-Jun-2026

6. Date on which Issuer notified

25-Jun-2026

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	5.010000	0.000000	5.010000	203320168
Position of previous notification (if applicable)	4.930000	0.000000	4.930000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
Ordinary GB00BN7SWP63		88958040		2.190000
ADRs US37733W2044		114362128		2.820000
Sub Total 8.A	203320168		5.010000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11. Additional Information

12. Date of Completion

25-Jun-2026

13. Place Of Completion

San Francisco, California, United States of America

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 26, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc